Benefits
Lean muscle mass increase without hormonal side effects
A single double-blind RCT (Isenmann 2019) found ecdysterone supplementation produced greater lean body mass gains than placebo in resistance-trained males, without changes in testosterone or DHT. This result has not been independently replicated: two other human trials (Wilborn 2006 and Dissemond 2025) found no significant lean-mass or performance benefit over placebo, so an established anabolic effect cannot be claimed.
Strength and exercise performance
Evidence for strength and performance is mostly preclinical (cell and animal studies) plus one contested human RCT (Isenmann 2019); two other human RCTs (Wilborn 2006, Dissemond 2025) reported no significant benefit over placebo. Proposed mechanisms include muscle protein synthesis via ERβ and mTOR signaling, but a human strength or performance benefit remains unconfirmed.
Anti-catabolic muscle preservation
In preclinical (cell and animal) studies, ecdysteroids have been reported to inhibit myostatin expression and reduce glucocorticoid-mediated muscle protein breakdown. These anti-catabolic effects are mechanistic and proposed; they have not been demonstrated as muscle-preservation outcomes in human trials.
Mechanism of action
Estrogen receptor beta (ERβ) agonism and mTOR activation
Ecdysteroids bind to estrogen receptor beta (ERβ) — not the androgen receptor — producing tissue-selective anabolic effects in skeletal muscle without the virilizing androgenic effects of testosterone or anabolic steroids. ERβ activation in muscle cells stimulates protein synthesis via PI3K/Akt/mTOR signaling and promotes muscle satellite cell proliferation. Simultaneously, ecdysteroids directly activate mTORC1 through a steroid receptor-independent membrane mechanism, providing complementary anabolic signaling. Myostatin suppression provides additional anti-catabolic support. These pathways are demonstrated mainly in cell and animal models and are proposed mechanisms rather than confirmed human effects.
Clinical trials
Randomized, double-blind, placebo-controlled 10-week trial of ecdysterone supplementation (200 mg or 800 mg/day) in 46 resistance-trained males combined with strength training and protein supplementation. Outcomes: lean body mass, bench press 1RM, body composition. (Isenmann et al. 2019, Arch Toxicol)
46 resistance-trained males. 10-week intervention.
Ecdysterone group gained significantly more lean body mass (+1.5 kg vs +0.5 kg placebo) and showed greater bench press strength gains vs placebo. Critical context: This trial led the authors to recommend ecdysterone BE added TO the WADA prohibited list for athletes — they considered the effects to be consistent with anabolic agent activity. Currently not on WADA list (as of mid-decade), but its status is debated. Independent replication of strength gains has been mixed; some athletes may legally use ecdysterone but should check current WADA list before competition.